Table 3.
Numbers of Medications and Classes in Value Sets, Value Set Consistency (κ), and Individual Drugs With Perfect Agreement Among References
| DDI | Drug A | Drug B |
|---|---|---|
| 1 | Amphetamine & Derivatives (n = 17, κ = 0.16*) Amphetamine, dextroamphetamine, lisdexamfetamine, methamphetamine |
MAOIs (n = 12, κ = 0.24*) Isocarboxazid, phenelzine, selegiline, tranylcypromine |
| 2 | Atazanavir (n = 6, κ = 0.11) Atazanavir |
PPIs (n = 11, κ = 0.49*) Esomeprazole, dexlansoprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole |
| 3 | Febuxostat (n = 2, κ = 0.47*) Febuxostat |
Azathioprine & Mercaptopurine (n = 2, κ = 1.00*) Azathioprine, mercaptopurine |
| 4 | SSRIs (n = 23, κ = 0.17*) Citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline |
MAOIs (n = 12, κ = 0.24*) Isocarboxazid, phenelzine, selegiline, tranylcypromine |
| 5 | Irinotecan (n = 1, κ = 1.00*) Irinotecan |
Strong CYP3A4 Inhibitors (n = 37, κ = 0.16*) Clarithromycin, indinavir, itraconazole, ketoconazole, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole |
| 6 | Narcotic Analgesics (n = 43, κ = –0.01) Fentanyl, meperidine, methadone, tapentadol, tramadol |
MAOIs (n = 13, κ = 0.20*) Isocarboxazid, phenelzine, selegiline, tranylcypromine |
| 7 | Tricyclic Antidepressants (n = 12, κ = 0.06) Clomipramine, imipramine |
MAOIs (n = 12, κ = 0.29*) Isocarboxazid, phenelzine, selegiline, tranylcypromine |
| 8 | High-risk QT Prolonging Agents (n = 114, κ = –0.06) Arsenic trioxide, disopyramide, dofetilide, ibutilide, procainamide, quinidine, sotalol, thioridazine |
High-risk QT Prolonging Agents (n = 114, κ = –0.06) Arsenic trioxide, disopyramide, dofetilide, ibutilide, procainamide, quinidine, sotalol, thioridazine |
| 9 | Ramelteon (n = 37, κ = –0.11) Ramelteon |
Strong CYP1A2 Inhibitors (n = 16, κ = –0.06) Ciprofloxacin |
| 10 | Strong CYP3A4 Inducers (n = 22, κ = –0.05) Carbamazepine, rifampin |
Protease Inhibitors (n = 22, κ = 0.39*) Atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir |
| 11 | HMG Co-A reductase inhibitors (n = 8, κ = –0.16) Lovastatin, simvastatin |
CYP3A4 and protease inhibitors (n = 41, κ = 0.08) Indinavir, nefazodone, nelfinavir, ritonavir, saquinavir |
| 12 | CYP3A4 & Protease Inhibitors (n = 34, κ = –0.23) Indinavir, nelfinavir, ritonavir, saquinavir |
Ergot alkaloids & derivatives (n = 7, κ = 0.07) Dihydroergotamine, ergotamine |
| 13 | Tizanidine (n = 1, κ = 1.00*) Tizanidine |
CYP1A2 Inhibitors (n = 18, κ = –0.05) Ciprofloxacin |
| 14 | Tranylcypromine (n = 13, κ = 0.11) Isocarboxazid, phenelzine, rasagiline, safinamide, tranylcypromine, selegiline |
Procarbazine (n = 13, κ = 0.11) Isocarboxazid, phenelzine, rasagiline, safinamide, tranylcypromine, selegiline |
| 15 | Triptans (n = 7, κ = 0.14) Sumatriptan, rizatriptan, zolmitriptan |
MAOIs (n = 12, κ = –0.12) Isocarboxazid, phenelzine, tranylcypromine |
Abbreviations: CYP1A2, cytochrome P450 isozyme 1A2; CYP3A4, cytochrome P450 isozyme 3A4; MAOI, monoamine oxidase inhibitor; PPI, proton pump inhibitor; SSRI, selective serotonin reuptake inhibitor. The symbol κ denotes Fleiss’ kappa statistic.
a P < 0.05.